, ITCI
--/--/-- --:--:-- Назад к новостям
| Дата: | --/--/-- --:--:-- |
| Id события: | E5CZL3OTR |
| Тип действия: | ACQUISITION |
| Статус действия: | COMPLETED |
| Символ покупателя: | |
| Целевой символ: | ITCI |
| Обновлено: | --/--/-- --:--:-- |
| Цена покупки за акцию: | 132 |
| Цена за акцию в валюте: | USD |
| Ссылки на новости: | https://www.businesswire.com/news/home/20250402861736/en/ |
Action Notes
Johnson & Johnson and Intra-Cellular Therapies, Inc announced today that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Intra-Cellular Therapies, a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, for $132.00 per share in cash for a total equity value of approximately $14.6 billion. The closing of the transaction is expected to occur later this year subject to applicable regulatory approvals, approval by Intra-Cellular Therapies' stockholders and other customary closing conditions for a transaction of this type. Following completion of the transaction, Intra-Cellular Therapies' common stock will no longer be listed for trading on the Nasdaq Global Select Market. The Intra-Cellular special shareholder meeting to vote on the transaction will be held on 03/27. Per PR on 4/1, Johnson & Johnson intends to complete its acquisition of Intra-Cellular Therapies on or around April 2, 2025. Following the completion of the transaction, Intra-Cellular Therapies' common stock will cease trading on the NASDAQ Global Select Market.
